An ailing AstraZeneca kicks two drugs out of the pipeline and an ex-drug partner’s share price is blasted
Last October Synairgen saw its shares clobbered by the news that its Big Pharma partner AstraZeneca had scrapped a mid-stage study of their inhaled …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
